放射科医生应如何将非影像前列腺癌生物标志物融入日常实践
本文综述了已知或疑似前列腺癌患者中非影像生物标志物的现有证据。血液和尿液检测可改善首次或重复活检时对临床显著疾病的预测并可能减少不必要活检;组织基因组和蛋白质组检测可独立评估侵袭性并补充影像。认识影像与生物标志物的交叉可改善临床照护和资源利用。
要点
- 血液和尿液生物标志物可改善首次或重复活检前对临床显著前列腺癌的预测。
- 血液和尿液生物标志物已与前列腺MRI联合评估,可能辅助MRI前、后决策。
- 组织基因组和蛋白质组检测可独立评估前列腺癌侵袭性并补充影像。
核心结论
- 越来越多的非影像生物标志物可用于辅助已知或疑似前列腺癌男性的临床决策。
- 认识影像与生物标志物的交叉可能改善前列腺癌患者的临床照护和资源利用。
研究设计与样本
- 综述,回顾已知或疑似前列腺癌患者中非影像生物标志物的现有证据。
临床应用与阅片要点
- 对于疑似前列腺癌、考虑首次或重复活检的患者,血液和尿液检测可改善对临床显著疾病的预测并可能减少不必要活检。
- 血液和尿液生物标志物已与前列腺MRI联合评估,可能辅助MRI前、后决策。
- 组织基因组和蛋白质组检测可独立评估前列腺癌侵袭性并补充影像。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To review the current body of evidence surrounding non-imaging biomarkers in patients with known or suspected prostate cancer.
RESULTS: Several non-imaging biomarkers have been developed and are available that aim to improve risk estimates at several clinical junctures. For patients with suspicion of prostate cancer who are considering first-time or repeat biopsy, blood- and urine-based assays can improve the prediction of harboring clinically significant disease and may reduce unnecessary biopsy. Blood- and urine-based biomarkers have been evaluated in association with prostate MRI, offering insights that might augment decision-making in the pre and post-MRI setting. Tissue-based genomic and proteomic assays have also been developed that provide independent assessments of prostate cancer aggressiveness that can complement imaging.
CONCLUSION: A growing number of non-imaging biomarkers are available to assist in clinical decision-making for men with known or suspected prostate cancer. An appreciation for the intersection of imaging and biomarkers may improve clinical care and resource utilization for men with prostate cancer.
引用
- Rajwa P, Syed J, Leapman MS, et al. How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice? Abdom Radiol (NY). 2020. PMID: 32232525. doi:10.1007/s00261-020-02496-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。